Table 1 Characteristics of the studies included in the metanalysis
Author | Number of patients and mean Age (years) | Males (%) statin/control group | Intervention | Follow-up | Total cholesterol (TC) and LDL cholesterol values before and after treatment with statin,mean mg/dl and % reduction | Co-morbidities (%) statin/control group | Concurrent Medications (%) statin/control group | Placebo-controlled/Double blind | Unsuccessful Cardioversion statin/control group (n) | Mean Left Atrial diameter (mm) Statin/control group | Jadad Score |
|---|---|---|---|---|---|---|---|---|---|---|---|
Almroth 2009[21] | 234 (65±10) | 76/74 | Atorvastatin 80 mg/day (started at least 14 days before EC) | 30 days | TC:202–136 (−32.6%) | H:47/48 D:7/10 CAD:4/4 | B:87/80 C:14/16 DG:16/20 | YES/YES | 8/13 | 44/43 | 5 |
LDL:123–65 (−52.8%) | |||||||||||
Ozaydin 2006[22] | 48 (62±11) | 71/50 | Atorvastatin 10 mg/day (started 48 hours before EC) | 3 months | TC:179–151 (−15.6%) | H:42/38 D:21/25 | B:33/25 C:21/42 DG:4/4 A:8/4 P:8/8 | NO/NO | 0 | 47/43 | 2 |
LDL:109–95 (−12.8%) | |||||||||||
Xia 2009[23] | 64 (61±8) | 69/63 | Rosuvastatin 10 mg/day (started 48 h before EC) | 3 months | TC:159–131 (−17.6%) | - | B:38/31 C:31/34 A:22/28 DG:13/6 | NO/NO | 0 | 41/41 | 1 |
LDL:97–83 (−14.4%) | |||||||||||
Tveit 2004[20] | 114 (68±10) | 79/75 | Pravastatin 40 mg/day (started 3 weeks before EC) | 6 weeks | Mean n.s. | H:42/44 D:9/4 COPD:11/11 CHD:9/12 | B:67/65 C:30/28 DG:25/23 F:6/4 A:2/4 | NO/NO | 11/11 | 45/43 | 3 |
TC:-22% | |||||||||||
LDL:-33% | |||||||||||
Demir 2011[25] | 44 (61±10) | 48/44 | Atorvastatin 40 mg/day (started 3 weeks before EC) | 2 months | TC:174–129 (−25.8%) | H:74/52 D:8/4 S:17/17 CHD:21/13 | A:91/87 P:4/8 C:22/26 | NO/NO | 1/1 | 42/43 | 1 |
LDL:112–62 (−44.6%) | |||||||||||
Negi 2011[24] | 64 (55±12) | 82/84 | Atorvastatin 80 mg/day (started at randomization: 0–7 days before EC) | 12 months | TC:183–142 (−22.4%) | H:52/49 D:12/3.2 S:24/16 CHD:12/13 | B: 49/68 | YES/YES | - | 46/46 | 4 |